2 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
Follow Inc280: new trials by email Literature Review of Inc280 trials Research Report on Inc280
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy Capmatinib, Osimertinib, Pemetrexed - Carcinoma, Non-Small-Cell Lung | Phase 3 | Terminated | Novartis Pharmaceuticals | 6 | 2021-09-22 | 2024-03-05 |
| Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation Capmatinib, Docetaxel - Carcinoma, Non-Small-Cell Lung | Phase 3 | Terminated | Novartis Pharmaceuticals | 22 | 2020-09-25 | 2025-05-16 |
Carcinoma, Non-Small-Cell Lung (2) · Carcinoma (1)
South Korea (2) · Belgium (1) · Brazil (1) · Bulgaria (1) · France (1) · Germany (1) · Hungary (1) · India (1) · Italy (1) · Japan (1) · Lithuania (1) · Malaysia (1) · Netherlands (1) · Portugal (1) · Russia (1)